Literature DB >> 24117261

Co-administration of aqueous ginseng extract with tobramycin stimulates the pro-inflammatory response and promotes the killing of Pseudomonas aeruginosa in the lungs of infected rats.

Misagh Alipour1, Abdelwahab Omri, Edmund M K Lui, Zacharias E Suntres.   

Abstract

North American ginseng is known to have immunomodulatory and antipseudomonal properties in vitro. In this study we investigated the effects of aqueous ginseng extract, either alone or in a combination with the antibiotic tobramycin, in an animal model of chronic Pseudomonas aeruginosa lung infection. The lungs of male rats (n = 5) were infected with P. aeruginosa (2 × 10(8) cfu/mL) in agar-beads by intratracheal instillation. Starting on day 7 post-infection, animals were treated daily for 3 consecutive days with saline, tobramycin (300 μg/kg body mass, intratracheal), and (or) ginseng (100 mg/kg body mass, subcutaneous); animals were sacrificed 24 h after the third drug treatment. Lung bacteria counts, cytokine levels in sera, and lung histopathology were examined. The treatment of infected animals with tobramycin [6.6 × 10(4) colony forming units (cfu)], ginseng (5.3 × 10(4) cfu), or tobramycin plus ginseng (2.0 × 10(3) cfu) lessened the lung infection compared with the control group (saline treated) (6.0 × 10(6) cfu). The levels of pro-inflammatory cytokines (IL-2, IL-4, IL-6, IL-12p70, IFN-γ, GM-CSF, TNF-α) in infected animals were significantly increased with co-treatment of ginseng plus tobramycin. These data suggest that co-administration of aqueous ginseng extract and tobramycin stimulated the pro-inflammatory response and promoted the killing of P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24117261     DOI: 10.1139/cjpp-2013-0073

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  1 in total

Review 1.  Pharmacological effects of ginseng on infectious diseases.

Authors:  Nguyen H Nguyen; Cuong Thach Nguyen
Journal:  Inflammopharmacology       Date:  2019-08-12       Impact factor: 5.093

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.